Pacira BioSciences, Inc.
General ticker "PCRX" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $1.1B (TTM average)
Pacira BioSciences, Inc. does not follow the US Stock Market performance with the rate: -14.9%.
Estimated limits based on current volatility of 1.8%: low 23.62$, high 24.50$
Factors to consider:
- Total employees count: 790 (+11.0%) as of 2024
- Top business risk factors: Labor/talent shortage/retention, Regulatory and compliance, Strategic risks and growth management, Product development risks, Market competition
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [17.83$, 30.01$]
- 2026-12-31 to 2027-12-31 estimated range: [17.32$, 29.46$]
Financial Metrics affecting the PCRX estimates:
- Positive: with PPE of 9.9 at the end of fiscal year the price was neutral
- Positive: Operating cash flow per share per price, % of 13.06 > 12.96
- Positive: -4.72 < Operating profit margin, % of 3.87
- Positive: Interest expense per share per price, % of 1.50 <= 3.29
- Positive: -3.36 < Return on assets ratio (scaled to [-100,100]) of 0.55
- Positive: 42.60 < Shareholder equity ratio, % of 54.79 <= 64.25
- Negative: Industry inventory ratio change (median), % of 0.52 > 0.31
- Negative: negative Industry operating cash flow (median)
Short-term PCRX quotes
Long-term PCRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $674.98MM | $700.97MM | $726.41MM |
| Operating Expenses | $587.30MM | $774.34MM | $698.31MM |
| Operating Income | $87.67MM | $-73.37MM | $28.10MM |
| Non-Operating Income | $-25.97MM | $10.27MM | $-11.23MM |
| Interest Expense | $17.31MM | $16.57MM | $17.45MM |
| R&D Expense | $76.26MM | $81.58MM | $117.31MM |
| Income(Loss) | $61.70MM | $-63.11MM | $16.87MM |
| Taxes | $19.75MM | $36.45MM | $9.84MM |
| Profit(Loss)* | $41.95MM | $-99.56MM | $7.03MM |
| Stockholders Equity | $870.13MM | $778.35MM | $693.11MM |
| Inventory | $104.35MM | $125.28MM | $152.86MM |
| Assets | $1,574.39MM | $1,553.52MM | $1,264.92MM |
| Operating Cash Flow | $154.65MM | $189.39MM | $151.99MM |
| Capital expenditure | $15.16MM | $10.64MM | $15.33MM |
| Investing Cash Flow | $77.54MM | $-83.28MM | $99.48MM |
| Financing Cash Flow | $-183.03MM | $17.36MM | $-369.63MM |
| Earnings Per Share** | $0.91 | $-2.15 | $0.16 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.